Late-breaking abstract at ERS Congress provides new estimate from leading researchers and key opinion leaders
PARIS -Wednesday 19 September 2018 [ AETOS Wire ]
(BUSINESS
WIRE)-- Roughly 175 million Europeans have obstructive sleep apnoea,
according to a late-breaking abstract presented by ResMed today at the
European Respiratory Society’s annual ERS Congress in Paris. Leading
researchers estimate 90 million Europeans have moderate to severe sleep
apnoea, meaning they experience at least 15 breathing events an hour
during sleep.
These
statistics are based on the latest scoring rules for determining one’s
apnoea–hypopnoea index (AASM 2012) and are connected with a 16-country
study announced in May 2018 that revealed an estimated 936 million
people worldwide have sleep apnoea, a chronic sleep-disordered breathing
condition associated with increased risk of mortality and reduced
quality of life.
The
new global prevalence is nearly tenfold higher than the previous one –
100 million – estimated by the World Health Organization in 2007.
European countries with the highest prevalence are:
Russia, 40 million
Germany, 26 million
France, 24 million
Ukraine, 13 million
Spain, 9 million
United Kingdom, 8 million
“This
data is a warning call to Europe’s doctors and other care providers to
properly identify, screen and diagnose these people so they can get the
life-changing treatment they need,” said Dr. Adam Benjafield, lead
researcher and ResMed’s vice president of Medical Affairs.
Benjafield said one sign of an at-risk patient is whether they have a related chronic medical condition:
83% of people with drug-resistant hypertension have sleep apnoea
77% of people with obesity
76% of people with chronic heart failure
72% of people with type 2 diabetes
62% of people with a prior stroke
49% of people with atrial fibrillation
“Doctors
should screen their patients if they have any of these conditions,”
said Benjafield, “especially if a patient has exhibited sleep
apnoea-related symptoms like snoring, daytime sleepiness or frequent
nighttime urination.”
About ResMed
ResMed
(NYSE: RMD) (ASX: RMD), a world-leading connected health company with
more than 5 million cloud-connected devices for daily remote patient
monitoring, changes lives with every breath. Its award-winning devices
and software solutions help treat and manage sleep apnoea, chronic
obstructive pulmonary disease and other respiratory conditions. Its
6,000-member team strives to improve patients’ quality of life, reduce
the impact of chronic disease and save healthcare costs in more than 120
countries. ResMed.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20180918005278/en/
Contacts
ResMed
For media:
Jayme Rubenstein
+1 858.836.6798
news@resmed.com
or
For investors:
Amy Wakeham
+1 858.836.5000
investorrelations@resmed.com
Permalink : https://www.aetoswire.com/news/175-million-europeans-have-sleep-apnoea-highlighting-scale-of-global-health-crisis/en